Sertraline and Buspirone Safety in Pregnancy and Breastfeeding
Sertraline is generally safe during pregnancy and breastfeeding, with minimal infant exposure through breast milk, while buspirone appears safe during breastfeeding with very low milk transfer, though pregnancy data remain limited.
Sertraline in Pregnancy
Sertraline does not appear to cause major congenital malformations overall, though some specific risks warrant discussion 1. First-trimester sertraline exposure has been associated with:
- Atrial/ventricular septal defects (RR 1.34,95% CI 1.02-1.76) - small absolute risk increase
- Craniosynostosis (RR 2.03,95% CI 1.09-3.75) - rare condition with minimal absolute risk
These associations must be weighed against the well-documented risks of untreated maternal depression, which include preterm birth, low birth weight, and poor maternal-infant bonding. The FDA label advises patients to notify their physician if pregnant or planning pregnancy 2.
Clinical approach: Continue sertraline at the lowest effective dose if needed for maternal functioning. The magnitude of documented risks is small, and discontinuation may pose greater harm to the mother-infant dyad 3.
Neonatal Adaptation
Third-trimester SSRI exposure, including sertraline, can cause transient neonatal signs 3:
- Continuous crying, irritability, jitteriness
- Tremors, hypertonia, respiratory distress
- Feeding difficulties, sleep disturbance
- Onset within hours to days after birth, typically resolving within 1-2 weeks
Monitor infants closely during the first week postpartum and arrange early follow-up after hospital discharge 3.
Sertraline During Breastfeeding
Sertraline is a first-line choice for breastfeeding mothers 3, 4. The evidence strongly supports its safety:
- 87.4% of infant serum levels were below detection limits in a meta-analysis of 167 samples 4
- No significant correlation between maternal and infant sertraline concentrations 4
- The active metabolite desmethylsertraline shows minimal activity and low infant exposure 4
- Sertraline provides infants <10% of the maternal weight-adjusted dose 3
- Recent 2024 data confirmed minimal excretion in breast milk with mostly undetectable infant plasma levels (15/15 infants had undetectable levels) 5
Practical recommendations:
- Continue therapeutic dosing during breastfeeding 3
- Routine infant serum sampling is not warranted 4
- Standard pediatric monitoring is sufficient 4
- Watch for decreased suck, sleep disturbances, or poor weight gain (rare) 3
Buspirone in Pregnancy
Pregnancy data for buspirone are extremely limited. The most rigorous available evidence comes from a 2022 prospective registry study 6:
- 68 evaluable first-trimester exposures (72 infants including twins)
- Zero major malformations observed 6
- This represents the only prospectively ascertained pregnancy outcome data
Critical caveat: The sample size is small, and absence of malformations in 72 infants does not definitively establish safety. The FDA label states patients should notify their physician if pregnant or planning pregnancy 7.
Clinical approach: Given limited data, buspirone should be used during pregnancy only when benefits clearly outweigh unknown risks. Consider switching to better-studied alternatives (e.g., sertraline) if feasible, particularly for anxiety disorders where SSRIs are also effective.
Buspirone During Breastfeeding
Buspirone appears very safe during breastfeeding based on 2024 pharmacokinetic data 8:
- Buspirone levels were below detection (<1.5 ng/mL) in all milk samples from 9 mothers taking 7.5-30 mg twice daily
- Low levels of active metabolite 1-PP were detected
- Relative infant dose (RID) ranged 0.21-2.17% - well below the 10% safety threshold 8
- No adverse effects reported in exposed infants 8
Practical recommendations:
- Buspirone can be used during breastfeeding with minimal concern
- Standard infant monitoring is appropriate
- No special precautions or serum sampling needed
Algorithm for Clinical Decision-Making
For Pregnancy:
- If patient is on sertraline and stable: Continue at lowest effective dose; counsel about small risks of cardiac defects/craniosynostosis versus risks of untreated depression
- If patient is on buspirone: Discuss limited safety data; consider switching to sertraline if treating anxiety/depression
- Monitor pregnancy carefully with standard obstetric care
- Arrange early postpartum follow-up for neonatal monitoring
For Breastfeeding:
- Sertraline is preferred - extensive safety data, minimal infant exposure 3, 5, 4
- Buspirone is acceptable - very low milk transfer, RID <2.2% 8
- Continue therapeutic dosing; do not reduce unnecessarily
- Monitor infant for adequate weight gain and developmental milestones through routine pediatric care
- No routine drug level monitoring required
Common pitfall: Unnecessarily discontinuing effective psychiatric medication during pregnancy/breastfeeding due to theoretical concerns, leading to maternal decompensation that poses greater risk to both mother and infant than continued treatment.